前列腺组织锌对前列腺癌的诊断价值

Prostatic Zn Determination for Prostate Cancer Diagnostic Value

目的研究用前列腺组织内锌含量结合前列腺特异性抗原(PSA)对前列腺癌的诊断价值。方法对符合前列腺癌诊疗指南规定的前列腺穿刺指征患者行前列腺系统穿刺活检,留取一份组织用ICP-MS测定前列腺组织内锌含量,其余组织行常规病理检查。同时收集患者的血清PSA、经直肠前列腺彩超结果、前列腺穿刺组织的病理结果等资料。结果根据病理结果,把患者分为前列腺良性增生组和前列腺癌组。前列腺良性增生组(n=20):血清PSA(6.691±5.920)ng/mL,前列腺组织锌含量(125.845±75.600)μg/g(湿重)。前列腺癌组:血清PSA:(68.390±59.000)ng/mL,前列腺组织锌含量(54.470±32.690)μg/g(湿重)。2组比较,差异均有统计学意义(P均<0.05)。结论前列腺癌组织锌含量明显低于前列腺良性增生组织。前列腺组织中锌含量的降低对前列腺癌的诊断具有一定的价值。

Objective To investigate prostate tissue zinc combination of prostate-specific antigen （PSA） for prostate cancer diagnosis. Methods For prostate cancer treatment guidelines in line with the provisions of the prostate puncture indication system, the patients were examined by prostate biopsy, an organization dedicated by ICP-MS determination of the prostate tissue content of zinc, and the rest of the organization routine pathological examination. At the same time, the data of serum PSA, the prostate through the rectum color ultrasound, and the pathology of the prostate puncture were analyzed. Results According to the results of pathology, the patients were divided into benign prostatic hyperplasia and prostate cancer group. Prostatic hyperplasia （n：20） ：PSA： （6. 691± 5. 920） ng/mL, prostate Zinc： （125. 845± 75. 600） μg/g（wet）. Prostate cancer group（n = 22） ： PSA： （68. 390 ±59. 000） ng/mL, prostate tissue zinc content： （54. 470 ± 32. 690）μg/g（wet）. Prostate tissue zinc content comparison between the two groups was statistically significant（P〈0.05）. Conclusion Prostate cancer zinc content was significantly lower than that of prostate hyperplasia. The prostate tissue content of zinc reduce prostate cancer diagnosis has a certain value.